ASPIRE, Wendy Nawarra, MSW & Maeve E. O’Connor, MD on the Changing Views at AAP on IVIG PANS/PANDAS

aspire.care/bl...
Dr. Maeve O’Connor: Well I think not only this study but a lot of studies that are ongoing currently are going to continue to change the perception and increase the acceptance. We have been so lucky to be able to present our data so far at the European Academy of Pediatrics, the European Academy of Immunology. We were in Brussels. We were in Portugal. We were at the Georgetown Meeting with Dr. Beth Latimer. We had great interest there from the audience. A lot of people there had great questions. So I think it is going to springboard acceptance within associations like the Academy of Pediatrics because you know their guidelines still don’t recognize this disease. They still don’t recognize the treatment of using IVIG for this disease. So as we know the data is always ahead of the acceptance. But I am hoping the more data we get, the faster global acceptance will occur. I think we are getting there. I would have, five years ago, said that this is going to take forever but as you mentioned in the last two to three years it has truly exponentially grown. I think doing studies like the one we did on IVIG and others are doing is going to make that even easier.